Tumour necrosis factor (TNF) is an important mediator of endotoxin-induced vascular collapse and other inflammatory reactions. Eicosanoids have been implicated in the pathogenesis of these responses. In order to explore further the potential interactions between TNF and eicosanoid metabolism in eliciting vascular responses, we studied the effects of TNF on the bovine endothelial cell line CPAE. TNF 
INTRODUCTION
Tumour necrosis factor (TNF) is a polypeptide cytokine produced primarily by monoctyes and macrophages in response to endotoxin and other immune and inflammatory stimuli (for review articles see [1, 2] ). TNF, also called cachectin, was originally described as an agent that induced haemorrhagic necrosis of experimental tumours [1] , and is now also thought to mediate septic shock, cachexia and other inflammatory reactions. The pluripotent effects of TNF also include bone resorption, collagenase production and eicosanoid synthesis, as well as vasculitis and haemorrhagic necrosis of transplanted tumours [3] and other tissues [4] . Thus TNF exerts many of its effects through stimulation and disruption of the vasculature.
The endothelial cell lining of the vasculature plays an important role in the regulation of the permeability and integrity ofthe blood vessels, and alteration in endothelial cell function has been shown to modify the morphological and biological activities of the vasculature [5] [6] [7] [8] . TNF may thus mediate at least some of its effects by interacting with the endothelial cell lining of the vasculature. TNF binds to specific cellular receptors [2, 4] , and this receptor-ligand interaction may result in activation of a number of intracellular processes, including phospholipase activation and eicosanoid synthesis. TNF has been reported to increase the synthesis of eicosanoids [9] [10] [11] [12] [13] , several of which are known to affect the vasculature. Thus, TNF may mediate at least some of its effects via stimulation of endothelial cells to increase eicosanoid synthesis. These eicosanoids could then affect adjacent endothelial cells or more distant target cells.
We have recently demonstrated that leukotriene D4, another potent vasoactive substance, induces eicosanoid production by endothelial cells [14] . This action requires RNA and protein synthesis, and thus is similar to other inflammatory agents such as thrombin and phorbol esters which also require RNA and protein synthesis in order to increase eicosanoid synthesis [15] [16] [17] . Transduction ofthis leukotriene D4receptor-ligand interaction results in a transient increase in phospholipase A2 activity [18] . Furthermore, the ability of leukotriene D4 to increase phospholipase A2 activity appears to be coupled through a guanine nucleotide-binding protein, possibly Ni, which is sensitive to the Bordatella pertussis toxin, islet-activating protein (IAP) [19] .
Recently we have isolated and characterized a phospholipase A2-activating protein (PLAP) that enhances phospholipase A2 activity [20] . PLAP was originally discovered and isolated by its antigenic and functional relatedness to melittin, a bee venom peptide. Melittin has been shown to stimulate phospholipase A2 activity [21] [22] [23] and has also been shown to affect mammalian cell functions. For example, melittin can increase eicosanoid synthesis in fibroblasts, smooth muscle and endothelial cells [22, 24, 25] . Thus, we have postulated that eicosanoid synthesis and phospholipase A2 activity may be regulated in mammalian cells by the synthesis of PLAP. The purpose of these experiments is to determine if TNF also increases phospholipase A2 activity and arachidonic acid-metabolite release in endothelial cells in the same manner as leukotriene D4, and to determine if TNF affects the synthesis of PLAP.
MATERIALS AND METHODS

Materials
The recombinant TNF-a used in these experiments was cloned, expressed in Escherichia coli and purified as previously described from normal human peripheralblood monocytes [26] . The specific activity of purified TNF-a was (2) (3) (4) The bovine endothelial cell line, CPAE, was obtained from the American Type Culture Collection (Rockville, MD, U.S.A.) and was used within 10 passages of receipt. These cells were grown as previously described [14] . Microscopy Cells were grown on glass coverslips (11 mm x 24 mm) for 24 h before being treated with TNF (1000 units/ml) for 20 min. The coverslips were then quickly rinsed three times in phosphate-buffered saline (PBS) before being fixed with 3 % formalin in PBS. The coverslips were examined using phase contrast optics.
Permeability assays
These assays were performed as described [32] 
I3HlArachidonic acid release and phospholipase assays
These experiments were performed as we have previously described [14, 18, 27, 28 ]. E.l.i.s.a. assays Antibodies used in these experiments were those prepared using melittin as an antigen [20] . This antibody has been shown to cross-react with the mammalian protein PLAP [20] and was used to quantify PLAP because antibodies to the mammalian protein are not yet available. However, in these cells, this antibody immunoprecipitated a unique protein of Mr 28 000 and had PLAP activity and appeared identical with the protein we have previously termed PLAP [16] . Pre-immune sera did not react with these cells (results not shown). Cells were grown in 96-well Linbro plates for 24 h and were in the log phase of growth. Cells were treated with TNF (1000 units/ml) for the indicated periods of time, quickly rinsed twice with PBS and then fixed for 20-30 min using a formalin/PBS solution (3 % v/v). The cells were then permeabilized with 50 ,1 of PBS containing 0.05 % (v/v) Tween 20 for 3 min before being rinsed with PBS. The plates were then filled to capacity with PBS containing 20 % fetal calf serum and placed at 4°C overnight. Antimelittin antibody was diluted 1: 1000 in PBS and 50 ,1 was added to each well. In control experiments the antiactin antibody was diluted 1: 1000 and used exactly as the anti-melittin antibody. The plates were then incubated at room temperature for 1 h before being rinsed three times (5 min each time) with PBS. The goat anti-rabbit antibody (peroxidase-conjugated) was diluted 1: 5000 in PBS and 50 1ld was added to each well. The plate was again incubated for 1 h at room temperature before being rinsed three times (5 min each time) with PBS. The peroxidase substrate o-phenylenediamine was added (1 mg/ml in 0.1 M-citrate buffer, pH 4.5, containing 0.12 % H202) in a final vol. of 100 ,u1 and allowed to react for approx. 10 min. The reaction was stopped by the addition of 25,u of NaF (0.1 M) to each well. The absorbance of each well was determined using an automatic plate reader, Titertek Multiskan model MC (Helsinki, Finland). Therefore, in each experiment, each time point was determined in eight wells. Thus the data shown were obtained from three separate experiments which represent the means for 24 wells. Inhibitor studies IAP (100 ng/ml) was added to the cells 1 h before the addition of TNF as previously described [19] . Cycloheximide and actinomycin D (100 ,tg/ml and 10 ,tg/ml respectively) were added 30 min before TNF treatment as previously described [14] . None of these treatments were cytotoxic during the course of these experiments (as determined by Trypan Blue dye exclusion).
H.p.l.c. of I3Hlarachidonic acid metabolites
Cells were incubated overnight in [3H]arachidonic acid (10 Ci/ml). The next day the monolayers were rinsed twice with saline and treated with TNF (1000 units/ml) for 10 min. The supernatants were then collected, acidified with phosphoric acid (final concn. 0.1 %) and extracted with two volumes of ethyl acetate. The organic layer was removed and reduced in volume to 200 1l under nitrogen before being analysed by h.p.l.c.
H.p.l.c. analysis was performed using a 4,m C-18 reverse-phase column (Waters, Boston, MA, U.S.A.). The eluant from the column was analysed using an on-line radioactivity detector (IN/US, Fairfield, NJ, U.S.A.). The mobile phase consisted of acetonitrile and acidified water (0.01 % phosphoric acid). A multi-step gradient was used to elute the column. The initial conditions were 28 % acetonitrile for the first 4 4°C (with constant agitation). The Sephadex particles were collected by centrifugation and washed three times using 5 ml of PBS containing 0.05 % Tween 20. Next, 100 ,1 of sample buffer [29] was added to the particles and the samples were boiled for 5 min. A volume of 50,1 was analysed using a 15 % denaturing acrylamide gel [29] .
RESULTS
Microscopy
The addition of TNF (100-1000 units/ml) to the CPAE endothelial cell line resulted in maximal cellular retraction, initially observed after 10 min of treatment ( Fig. lb) and becoming more pronounced after 20 min of treatment (Fig. lc) . Maximal retraction was obtained with 1000 units/ml of TNF, therefore all subsequent experiments were performed using this dose. Similar morphologic results were observed by other investigators using endothelial cells obtained from different sources [30] . These results indicate that the CPAE cells respond to TNF and suggest that cellular retraction is a possible mechanism by which TNF increases the permeability of the vasculature. It was also observed that pretreatment of the cells with the eicosanoid-biosynthesis inhibitor, BW755c [31] , blocked these morphological changes (results not shown), suggesting that they were dependent on eicosanoid biosynthesis. In order to attempt to quantify this morphological phenomena, permeability assays were performed. Permeability assays
The recently described permeability assay [32] Fig. 1 was observed) . Pretreatment of the cells with BW755c (10 #sm for 30 min) inhibited not only the morphological retraction observed microscopically but also the diffusion of radioactive material from the upper to the lower chamber (Fig. 2) (Fig. 4) Fig. 5 ). This increase in phospholipase A2 activity was transient (Fig. 5) , reaching maximal activity by 5 treated with a variety of inhibitors. The increase in phospholipase A2 activity was abrogated by pretreating the cells with cycloheximide, actinomycin D or IAP (Table 2 ). These results suggest that the TNF receptor may be coupled through an IAP substrate (possibly N1)
and that both transcription and translation are necessary for TNF to increase phospholipase A2 activity. These inhibitors not only blocked the increase in phospholipase A2 activity but also blocked both the release of
[3H]arachidonic acid metabolites, and the increased rate of diffusion observed with iodinated protein A ( Table 3 ). E.l.i.s.a. assay for PLAP The previous experiments suggest that a protein was synthesized in response to TNF treatment that resulted in an increase in phospholipase A2 activity. To demonstrate that these antibodies recognized a single protein in the cells, cell sonicates were radiolabelled using 125TI Bolton-Hunter reagent which was then reacted with anti-melittin antibodies. The immunoprecipitants were analysed by gel electrophoresis (Fig. 6) . We observed that the predominant protein isolated by this technique had an Mr of 28 000, similar in size to the PLAP previously isolated by us from mouse smooth-muscle Table 2 . Inhibition of PLA2 activation
The previous experiment indicated that TNF increased phospholipase A2 activity after 5 min of treatment. In this experiment cells were pretreated with inhibitors of protein and RNA synthesis. The concentrations and time of pretreatment were sufficient to block > 95 % of the incorporation of [3H]leucine or [3H]uridine into acid-precipitable material, yet they were not sufficient increase the cells' permeability to Trypan Blue. We have previously shown that the concentration and time of IAP pretreatment were sufficient to ribosylate essentially all of the Mr 41 000 protein (N1) that is in these cells [19] . The values shown represent the means +S.D. of at least three experiments. Cycloheximide (CX) (100 ,ug/ml) and actinomycin D (AD) (10 ,ug/ml) were added 30 min before TNF, and IAP (100 ng/ml) 60 min before. [20] .
cells [25] . An e.l.i.s.a. assay using antibodies which recognize PLAP was performed (Fig. 7) . PLAP induction was maximal by 2-5 min following treatment with TNF, and returned to baseline levels by [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [1, 2, 4] . Several investigators have implicated pathophysiological roles for endothelial cells and eicosanoid production in the transduction of these disease processes [1, 7, 12, 25, 33] .
The CPAE endothelial cell line was used as a model system for examining the effects of TNF in vitro. Cells were treated with TNF and observed for morphological changes by microscopy. This response was maximal following 10 min of TNF treatment, and was abrogated by pretreatment with the eicosanoid synthesis inhibitor, BW755c. The cells responded in a physiologically relevant manner (i.e. retracted) which may be a mechanism by which the vasculature loses its integrity in response to TNF [3, 8] . The simple permeability assay used here demonstrated further that treatment of these cells with TNF increased the diffusion of macromolecules through confluent monolayers of these cells. This endothelial response in vitro, appears to be similar to the increased plasma exudation observed in vivo, and supports the concept that the endothelial cells may regulate vascular permeability.
The rate-limiting step in eicosanoid production is phospholipase hydrolysis of eicosanoid precursor fatty acid from membrane phospholipids [34] . TNF increased the amount of phospholipase A2 activity observed when phosphatidylcholine was used as a substrate phospholipid, but not when phosphatidylethanolamine was used. Furthermore, specificity of TNF was observed as phospholipase C activity remained unchanged when assayed by this technique. The time course of phospholipase A2 activation also coincided with the increased release of [3H]arachidonic acid metabolites. In other experiments we observed that the increase in phospholipase A2 activity was dose dependent with the maximal increase obtained with 100-1000 units of TNF/ml (results not shown). Similar concentrations induce eicosanoid synthesis by human umbilical vein endothelial cells [12] , human synovial cells [10] , dermal fibroblasts [10] , and rodent macrophages [9] . These same concentrations also stimulate bone resorption and inhibition of bone formation, processes mediated, at least in part, by eicosanoids [35] .
We had previously observed a similar transient increase in phospholipase A2 activity in these endothelial cells in response to leukotriene D4, an event which was dependent on RNA and protein synthesis [18] . To determine if the increase in phospholipase A2, activity in response to TNF was under similar control, cells were pretreated with cycloheximide and actinomycin D before TNF treatment. Both of these reagents inhibited the increase in phospholipase A2 activity in response to TNF. We have recently identified a protein which is able to increase phospholipase A2 activity that we have termed PLAP [20] . This protein is antigenically related to melittin, a well described bee venom peptide that stimulates phospholipase A2 activity [21] [22] [23] , and e.l.i.s.a. assays for this protein using anti-melittin antibody indicated that TNF increases the synthesis of PLAP. Melittin is a peptide isolated from bee venom that stimulates not only phospholipase A2 activity but also eicosanoid synthesis [12, 21, 22, 25] in mouse and human fibroblasts, rabbit aorta endothelial cells, rat pneumocytes, rabbit smooth-muscle cells, peripheral blood after intraperitoneal injection in mice [24] , and human endothelial arterial and venous cells [25] . These arachidonic acid metabolites have previously been implicated in endothelium-dependent vasodilation induced by melittin [33] . Similar phospholipase stimulatory proteins have been found in numerous other cell types from various species [21, 22, 31] . Thus there is precedence for our findings of PLAP in these cells and its potential role in endothelial cell retraction and eicosanoid synthesis.
In summary we propose that the CPAE cells used in these experiments may be a useful model system for studying the effects of TNF on the endothelium. The results described here indicate that eicosanoids, which are produced in response to TNF, may regulate, at least in part, some of the responses of the endothelium. We found that phospholipase A2 appeared to be activated by a process that required RNA and protein synthesis. We have also demonstrated an increase in the amount of PLAP detected in these cells following TNF treatment. The time course of the induction of PLAP correlates with the induction of phospholipase A2 activity. However, in order to conclusively prove the role of PLAP in this response, genetic manipulation of the PLAP gene will be required.
